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ABSTRACT 
There is paucity of data on the contribution of HIV infection to obstetric haemorrhage-
related severe maternal outcomes (SMO) with some literature suggesting an increased 
risk in HIV-infected women. Since the leading causes of maternal mortality in South 
Africa are non-pregnancy related infections, mainly HIV-related, and obstetric 
haemorrhage, there is a possible relationship between HIV infection and obstetric 
haemorrhage-related SMO. Hence the aim of this study was to determine whether 
obstetric haemorrhage-related SMO are increased in HIV-infected women. 
A retrospective study of cases of obstetric haemorrhage-related SMO at Chris Hani 
Baragwanath Academic Hospital, from January to December 2015 was conducted. A 
total of 73 women had obstetric haemorrhage-related SMO. Of these, 18 (24.7%) 
women were HIV-infected and 50 (68.5%) uninfected. All the HIV-infected women were 
on antiretroviral therapy, 50% initiated pre-pregnancy, and the median CD4 count was 
409 cells/mm3. There were 65 near-misses, 49 (72.1%) in HIV-infected women, and 
there were three maternal deaths, two in HIV-infected women.  
Previous caesarean section was the commonest identifiable factor associated with 
obstetric haemorrhage, 6/18 (33.3%) in HIV-infected women and 9/50 (18.0%) in 
uninfected women. The commonest cause of haemorrhage was postpartum 
haemorrhage, diagnosed in 65/68 (95.6%) women, and there was no significant 
difference between HIV-infected and uninfected women. There were no significant 
differences in the medical and surgical interventions the patients needed. 
Obstetric haemorrhage-related SMO were not increased in HIV-infected women in this 
study likely because it was a relatively healthy population of HIV-infected women. 
Larger studies are needed to elucidate these findings. 
 
 
 
vii 
 
CONTENTS 
DECLARATION          ii 
DEDICATION          iii 
PRESENTATIONS          iv 
ACKNOWLEDGEMENTS         v  
ABSTRACT           vi  
LIST OF ABBREVIATIONS        x 
LIST OF FIGURES          xi 
LIST OF TABLES          xii 
CHAPTER ONE – INTRODUCTION        1 
1.1 BACKGROUND         1 
1.2 PROBLEM STATEMENT       2  
1.3 JUSTIFICATION        2  
CHAPTER TWO – LITERATURE REVIEW       4  
2.1 THE BURDEN OF OBSTETRIC HAEMORRHAGE   4  
2.2 MATERNAL MORTALITY STATISTICS     5 
2.3 SEVERE MATERNAL OUTCOME AS A BETTER INDICATOR FOR 
 EVALUATING QUALITY OF MATERNAL CARE   5 
2.4 HIV INFECTION, OBSTETRIC HAEMORRHAGE AND SMO: THE 
INTERSECTION         8 
CHAPTER THREE – METHODS         12  
 3.1 STUDY SETTING        12  
viii 
 
 3.2 STUDY DESIGN        12  
 3.3 STUDY POPULATION        12 
 3.4 SUBJECTS         13 
3.4.1 Inclusion criteria       13  
3.4.2 Exclusion criteria       13 
3.5 DATA COLLECTION AND DATA ANALYSIS    13 
3.6 ETHICS           14 
CHAPTER FOUR – RESULTS         15 
 4.1 DEMOGRAPHICS AND ANTENATAL DETAILS    16  
 4.2 DELIVERY DETAILS        16 
4.3 ANTEPARTUM HAEMORRHAGE      19 
4.4 POSTPARTUM HAEMORRHAGE       19 
4.5 INTERVENTIONS USED IN THE MANAGEMENT OF POSTPARTUM 
HAEMORRHAGE         20  
4.6 BLOOD TRANSFUSIONS IN WOMEN WITH OBSTETRIC HAEMORRHAGE 
           22 
4.7 BLOOD RESULTS        22 
4.8 SEVERE MATERNAL OUTCOMES      23 
4.9 DETAILS OF THE MATERNAL DEATHS     25 
4.9.1 Case 1         25 
4.9.2 Case 2         25  
4.9.3 Case 3         26 
ix 
 
CHAPTER FIVE – DISCUSSION        27  
5.1 ANTENATAL AND INTRAPARTUM FACTORS ASSOCIATED WITH 
OBSTETRIC HAEMORRHAGE       27 
5.2 CAUSES OF OBSTETRIC HAEMORRHAGE    29  
5.3 INTERVENTIONS USED IN THE MANAGEMENT OF POSTPARTUM 
HAEMORRHAGE         29 
5.4 NEAR-MISSES AND MATERNAL DEATHS    30 
5.5 LIMITATIONS         32 
5.6 STRENGTHS         32  
5.7 CONCLUSION         32 
5.8 RECOMMENDATIONS       33  
REFERENCES           34 
APPENDICES           38 
 DATA COLLECTION TOOL       38 
 ETHICS CLEARNCE CERTIFICATE      47 
 TURNITIN ORIGINALITY REPORT      48 
 
 
 
 
 
 
x 
 
LIST OF ABBREVIATIONS  
APH = Antepartum Haemorrhage  
ART = Antiretroviral therapy 
BDACS = Bleeding during or after caesarean section 
CHBAH = Chris Hani Baragwanath Academic Hospital 
ELCS = Elective Caesarean Section 
EMCS = Emergency Caesarean Section 
FDC = Fixed dose combination 
Hb = Haemoglobin 
HAART = Highly Active Antiretroviral Therapy 
HIV = Human Immunodeficiency Virus 
IQR = Interquartile range 
NHLS = National Health Laboratory Services 
MMR = Maternal Mortality Ratio 
OH = Obstetric Haemorrhage 
PPH = Postpartum Haemorrhage 
REDCap = Research Electronic Data Capture 
SAMM = Severe Acute Maternal Morbidity 
SD = Standard Deviations 
SMO = Severe Maternal Outcome  
WHO = World Health Organization 
xi 
 
LIST OF FIGURES 
4.1 A summary of severe maternal outcomes with HIV status    15 
4.2 Causes of PPH          20  
4.3 The frequency of medical agents used in the management of PPH  20 
4.4 The frequency of surgical interventions used in the management of PPH 21 
4.5 Amount of blood products transfused      21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xii 
 
LIST OF TABLES 
CHAPTER TWO 
2.1 The three approaches used to identify maternal near-miss   6 
2.2 Changes in PMTCT and ART guidelines       8 
CHAPTER FOUR 
4.1 Demographics and antenatal details       17  
4.2 Labour and delivery details        18 
4.3 Causes of Antepartum haemorrhage       18 
4.4 Worst blood results during hospital admission     22  
4.5 Markers for near-miss related to obstetric haemorrhage    23 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
CHAPTER ONE 
INTRODUCTION 
1.1 BACKGROUND 
Obstetric haemorrhage includes both antepartum haemorrhage (APH) and postpartum 
haemorrhage (PPH) from any cause, known or unknown.1,2 According to a WHO 
systematic analysis between from 2003 to 2012 it is the leading cause of maternal 
mortality worldwide accounting for 27.1% of global maternal deaths.3 In Africa it is 
estimated that up to 25% of maternal deaths were due to obstetric haemorrhage in 
2014.3 In the sixth triennial report on the Confidential Enquiries into Maternal Deaths in 
South Africa (Saving Mothers), obstetric haemorrhage contributed significantly to 
maternal mortality.4 It has been identified as the second most common cause of 
maternal mortality after non-pregnancy related infections.4 According to the report, 
prolonged labour and anaemia were found to be the commonest underlying factors for 
obstetric haemorrhage, and bleeding during or after caesarean is increasingly becoming 
an important cause of obstetric related maternal death.4 
Although maternal mortality presents a significant public health concern, deaths are rare 
in absolute numbers. Analysing maternal deaths, especially within the context of an 
institution, does not allow for comprehensive assessment of the quality of maternal 
healthcare.5 Maternal near-misses, which occur more frequently than maternal deaths, 
have been identified as better indicators of quality of care.6 A maternal near-miss is a 
woman who nearly died but survived a complication that occurred during pregnancy or 
childbirth, or within 42 days of termination of pregnancy.6 Similar inadequacies in 
healthcare systems contribute to both maternal deaths and near-misses, together 
defined as severe maternal outcomes (SMO).7 By studying SMO, information can be 
obtained about the processes that take place in healthcare systems responsible for 
maternal healthcare, and also identify obstacles that need to be overcome to prevent 
adverse outcomes. Therefore, assessing SMO provides the most robust indicator for 
evaluating the quality of maternal health care.6,8–10 
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Before the widespread availability of antiretroviral therapy (ART), HIV-infected pregnant 
and postpartum women were said to experience greater morbidity and mortality than 
HIV-uninfected women. 11,12 The negative effect of HIV infection on maternal health is 
well documented in South Africa, with the high HIV seroprevalence among pregnant 
women and non-pregnancy related infections, largely HIV-related, being the leading 
cause of maternal deaths.11,13,14 
1.2 PROBLEM STATEMENT 
Few studies in South Africa have looked into the interrelation of obstetric haemorrhage, 
HIV-infection and SMO since the widespread availability of ART, and since the adoption 
of SMO as a tool to assess the quality of maternal care. In a population-based study 
done in the Pretoria Academic Hospital Complex, South Africa (August 2013 to July 
2014), 2.5% of pregnant and postpartum women had severe haemorrhage but 
contributed to 37.5% of all SMO.15 The HIV infection rate was 13.7% in women with 
SMO, lower than the seroprevalence in the study population which was 19.9%.15 The 
study found that the risk of obstetric haemorrhage was not higher in HIV-infected 
women.15 In another cross-sectional study done in 2012 at four major hospitals in South 
Africa, it was found that HIV status was not associated with obstetric haemorrhage, but 
was associated with a greater likelihood of blood transfusion.16 The study found a 
significantly higher rate of peripartum transfusion in HIV-infected than HIV-uninfected 
patients.16 In those patients who received transfusions, the number of red blood cell 
units received did not differ significantly by HIV status16 These results are a few 
important steps toward elucidating the impact of HIV on obstetric haemorrhage-related 
SMO. 
1.3 JUSTIFICATION 
There is paucity of data on the contribution of HIV infection to obstetric haemorrhage-
related SMO. Since the two commonest causes of adverse maternal outcomes in South 
Africa are non-pregnancy related infections, which are mostly HIV-related, and obstetric 
haemorrhage, there is the possibility of a relationship between HIV infection and 
obstetric haemorrhage-related SMO. It is therefore important to determine this 
relationship, the maternal risk factors involved, and the proportion of maternal deaths 
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and cases of near-misses from obstetric haemorrhage in HIV-uninfected and -infected 
women for an accurate comparison. Hence the aim of this study was to determine 
whether obstetric haemorrhage-related SMO are increased in HIV-infected women, 
compared to HIV-uninfected women, at Chris Hani Baragwanath Academic Hospital 
(CHBAH). 
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CHAPTER TWO   
LITERATURE REVIEW 
2.1 THE BURDEN OF OBSTETRIC HAEMORRHAGE 
Obstetric haemorrhage includes both APH and PPH from any cause known or 
unknown.1 APH is defined as bleeding from, or into the genital tract, occurring from 
24+0 weeks of pregnancy and prior to the birth of the baby.2 It may be due to abruptio 
placenta, placenta praevia, placenta accreta, uterine rupture, vasa praevia and amniotic 
fluid embolism, or may be APH of unknown cause.2 PPH may be defined in several 
ways and include blood loss of 500ml or more at vaginal delivery, or 1000ml or more at 
caesarean section.17 It is also defined as bleeding associated with a drop in haematocrit 
of 10% or more, either at vaginal delivery or caesarean section.17 Defining PPH 
however as vaginal bleeding or blood loss at caesarean section associated with 
hypotension and tachycardia, or bleeding at delivery necessitating blood transfusion 
eliminates the high degree of subjectivity in the measurement of blood loss at delivery 
and the practical challenges associated with measuring haematocrit routinely.17 
Obstetric haemorrhage is a major public health concern worldwide.18  As mentioned 
previously, obstetric haemorrhage is the second leading cause of maternal deaths in 
South Africa.4 According to the sixth Saving Mothers report (2011-2013), the 
commonest causes of PPH were identified as bleeding during or after caesarean 
section (BDACS) (32.3%); abruptio placentae (16.1%), uterine rupture (15.1%), uterine 
atony (7.3%) and retained products of conception (6.6%).4 Over the past decade 
BDACS has become the most important cause of obstetric haemorrhage-related 
maternal deaths.19 The case fatality rates have increased from 20.9 per 100 000 
caesarean deliveries in the first triennial Savings Mothers report (2002-2004) to 33.6 per 
100 000 caesarean deliveries in the sixth report (2011-2013).19 Though the reasons why 
these women bleed are mostly difficult to determine, deaths have been attributed to 
inadequate surgical skill, poor peri-operative monitoring, failure in recognizing on-going 
bleeding, delay in escalating interventions, insufficient staffing and unavailability of 
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emergency blood products.19 A caesarean section duration of between 30 to 50 minutes 
is deemed to be acceptable.20 
2.2 MATERNAL MORTALITY STATISTICS 
Maternal death is defined by the World Health Organization (WHO) as “the death of a 
woman while pregnant or within 42 days of a termination of pregnancy, irrespective of 
the duration and site of a pregnancy, from any cause related to or aggravated by the 
pregnancy or its management but not from accidental or incidental causes”.21 In 2015, it 
was estimated that almost 303,000 women die each year from complications of 
pregnancy and childbirth, and two thirds of them occur in sub-Saharan Africa.5 In South 
Africa, about 1,500 maternal deaths occur every year, representing an estimated 
maternal mortality ratio (MMR) of 132/100 000 live births in 2015.7 This is a reduction 
from the 2010 ratio of 154/100 000 live births, but fell short of the millennium 
development goal of a 75% reduction in MMR between 1990 and 2015.5 Although 
maternal mortality presents a significant public health concern, deaths are rare in 
absolute numbers, and analysing maternal deaths alone does not allow for a 
comprehensive assessment into the quality of maternal healthcare.8 Hence SMO have 
been suggested as a better indicator of quality of maternal healthcare. 
2.3 SEVERE MATERNAL OUTCOME AS A BETTER INDICATOR FOR EVALUATING 
QUALITY OF MATERNAL CARE 
As mentioned in the introduction, severe acute maternal morbidity (SAMM) or maternal 
near-miss (used interchangeably) is a woman who nearly died, but survived a 
complication that occurred during pregnancy or childbirth, or within 42 days of 
termination of pregnancy.7 In the late 1990s and early 2000s evaluating SAMM was 
proposed as a surrogate analysis into maternal deaths and an enormous amount of 
work has been done to standardize the definition of near-miss.6–9,22 The WHO Working 
Group on Maternal Morbidity and Mortality classification has three approaches for using 
as a quality of care tool to identify maternal near-miss cases: the clinical criteria related 
to a specific disease entity, the intervention-based criteria, and the organ system 
dysfunction-based criteria.8 A summary of these approaches is presented in Table 2.1. 
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Table 2.1 The three approaches used to identify maternal near-miss.8 
Clinical criteria related to a speciﬁc disease 
entity 
Speciﬁc diseases are used as the starting points 
and then for each disease, morbidity is deﬁned. 
For example, pre-eclampsia is the disease entity, 
and complications such as renal failure, eclampsia 
and pulmonary oedema are used to deﬁne severe 
morbidity 
Intervention based criteria Interventions such as admission to an ICU, the 
need for an emergency hysterectomy, the need for 
a blood transfusion, caesarean section are used as 
markers of maternal near-miss 
Organ system dysfunction based criteria In this system, there is a sequence of events: a 
clinical insult, followed by a systemic inﬂammatory 
response syndrome, organ dysfunction and organ 
failure leading to death. Maternal near-miss cases 
are those women with organ dysfunction and organ 
failure who survive. The criteria for deﬁning a 
maternal near-miss are deﬁned per organ system. 
Markers for organ system dysfunction or failure are 
speciﬁed 
 
After a systematic review of primary studies that used the various criteria for case 
finding, the advantages and disadvantages were compared. Application of the organ 
system dysfunction-based criteria was recommended for case finding because it 
eliminates the wide variation in outcome that is associated with the clinical criteria and 
the likely exclusion of many maternal near-miss cases because of variable  accessibility 
when management-based criteria are used 8. The organ system dysfunction-based 
criteria for identification of near-miss are summarized below: 
Cardiovascular dysfunction 
• Shock, cardiac arrest (the absence of pulse/heart beat and loss of 
consciousness), use of continuous vasoactive drugs, cardiopulmonary 
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resuscitation, severe hypoperfusion (lactate > 5mmol/l or >45mg/dl) and severe 
acidosis (pH<7.1). 
Respiratory dysfunction 
• Acute cyanosis, gasping, severe tachypnoea (respiratory rate >40 breaths/min), 
intubation and ventilation not related to anaesthesia, and severe hypoxemia (02 
<90% for >60minutes or more or PAO2/Fi O2 <200). 
Renal Dysfunction  
• Oliguria non-responsive to fluids or diuretics, dialysis for acute renal failure, and 
severe acute azotaemia (creatinine ≥300µmol/ml or >3.5 mg/dL). 
Coagulation/Haematological Dysfunction 
• Failure to form clots, massive transfusion of blood or red cells (≥5units), and 
severe acute thrombocytopenia (50000 platelets/ml). 
Hepatic dysfunction 
• Jaundice in the presence of pre-eclampsia, and severe acute hyperbilirubinemia 
(bilirubin >100µmol/ml or 6.0mg/dl). 
Neurological Dysfunction  
• Prolonged unconsciousness (lasting ≥12hours) or coma and the underlying 
aetiology include metabolic causes, cerebrovascular accidents, uncontrollable 
seizures/status epilepticus, and total paralysis. 
Uterine dysfunction 
• Uterine haemorrhage or infection leading to hysterectomy.7 
Similarities, and sometimes differences, have been found in the patterns of disease in 
maternal deaths and SAMM. In 2003, Pattinson et al found that South African women 
with SAMM have a higher preponderance of conditions like obstetric haemorrhage that 
were more amenable to interventions. 6 Maswime et al in 2017 identified previous 
caesarean section as an important common risk factor for obstetric haemorrhage-
related near-miss in Johannesburg, South Africa.23 Consistently in the Saving Mothers 
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reports, deaths occur more in women with medical conditions like advanced HIV 
disease.4 Pacagnella et al however described similarities in the delays in care 
associated with both deaths and near-misses in a multicentre cross-sectional study in 
Brazil.10 Despite these differences in findings there appear to be similar inadequacies in 
the health system leading to both maternal deaths and near-misses. Review of SAMM 
gives information that complements the findings of maternal death enquiries.6 
2.4 HIV INFECTION, OBSTETRIC HAEMORRHAGE AND SMO: THE 
INTERSECTION                                                                                                                                                                    
At a seroprevalence rate of up to 30% among pregnant women, South Africa has one of 
the highest HIV prevalence rates in the world.12,14 Since 1997, detailed data on maternal 
deaths in South Africa have been available in the form of triennial Confidential Enquiry 
reports, the Saving Mothers reports, and consistently, non-pregnancy related infections, 
largely HIV-related, have been found to be the leading causes of maternal deaths.4 
 Prior to the widespread roll-out of ART in South Africa, HIV-infected women 
experienced more morbidity and mortality than HIV-uninfected women.11 In 2004, ART 
was introduced in South African public health facilities for women with CD4 counts of 
less than 200/µL.24 This was expanded to include women with CD4 less than 350/µL in 
2010 and from 2013, all pregnant and breastfeeding women became eligible to initiate 
ART irrespective of CD4 count.25,26 These periods of changes in government policy 
regarding ART provision are summarized in Table 2.2. Its impact on direct causes of 
maternal death is yet to be ascertained.  
Table 2.2 Changes in PMTCT and ART guidelines 24–29 
Year  Guideline changes  
 PMTCT guidelines  
2002 Intrapartum single-dose nevirapine  
2008 Antenatal zidovudine  
2013 ART for all HIV-infected pregnant women, stopped after breastfeeding if not eligible for life-long treatment 
2015 Lifelong ART for all HIV-infected pregnant women 
 ART guidelines  
2004 Life-long ART with CD4 <200 cells/µl, or WHO stage 4 disease 
2010 For pregnant women, lifelong ART if CD4 ≤350 cells/µl, or WHO stage 3 or 4 disease  
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Anaemia is the commonest haematological abnormality with HIV infection and the 
severity of anaemia correlates with the severity of the HIV disease. 30,31 
Thrombocytopenia is also frequently associated with HIV infection and appears to 
worsen with progressively lower CD4 counts.32 Pregnant HIV-infected women are 
observed to have lower pre-delivery haemoglobin (antenatal anaemia) compared with 
HIV-uninfected women, putting HIV-infected women at an increased risk for obstetric 
haemorrhage.30,31 Antiretroviral therapy has the potential to improve anaemia and 
thrombocytopenia in HIV-infected pregnant women, and hence to decrease their risks 
for obstetric haemorrhage.31 
The evidence on the effect of HIV and its treatment on obstetric haemorrhage is 
conflicting. While Kourtis et al found no increased odds of APH in HIV-infected women 
in the United States of America who were not on ART from 1994 to 2003,33 other 
studies found that HIV-infected women on ART had increased odds for APH but not 
PPH, compared to HIV-uninfected women.34,35 Also, in a systematic review by Calvert et 
al to establish whether HIV-infected women are at increased risk of direct obstetric 
complications, the results were inconsistent.36 Whilst HIV was associated with an 
increased risk of antepartum haemorrhage in some studies, there was no evidence of 
an increased risk of placenta praevia, abruptio placenta, postpartum haemorrhage or 
retained placenta in others.36 
Few studies in Southern Africa have looked into the interrelation of obstetric 
haemorrhage, HIV infection and SMO since the widespread availability of ART, and 
since the adoption of SMO to assess maternal care. In a retrospective study in Durban 
to determine an association between increasing rates of obstetric haemorrhage and HIV 
or its treatment (2009 - 2011), HIV-infected women suffered more maternal near miss 
(hysterectomy, ICU admission) and deaths than uninfected women.37 In 2012, a cross-
sectional study looking at peripartum patients who had an obstetric haemorrhage and, 
or were transfused, was conducted at four major hospitals in South Africa, including 
CHBAH.16 HIV status was not associated with obstetric haemorrhage, but HIV 
seropositivity was associated with a significantly higher incidence of peripartum 
transfusion, after controlling for known confounders.16 Among HIV-infected women, 
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3.7% received a blood transfusion compared to 2.4% of HIV-uninfected.16 Risk factors 
for a peripartum blood transfusion included a prenatal haemoglobin of 9.2 g/dL or less, 
receiving no prenatal care (unbooked), and high gravidity.16 There was an association 
between blood transfusion and combination ART, where women on combination ART 
received significantly more blood products when compared to no therapy or HIV-
uninfected mothers.16 Interestingly, HIV-infected mothers with a CD4 count less than 
200/µL were less likely to sustain obstetric haemorrhage compared to those who were 
HIV-uninfected.16 An explanation for this finding is difficult, as it is generally expected 
that the associated poor immune status would predispose such women to greater 
pregnancy related morbidity. 
A descriptive population-based study to determine the spectrum of severe maternal 
morbidity and mortality in all women who delivered in eight obstetric units in the Pretoria 
Academic Hospital Complex, South Africa, was conducted between August 2013 and 
July 2014 and included 26 614 women.15 The HIV infection rate was 19.9% in the 
general population and the incidence of obstetric haemorrhage was 2.5%. While 
obstetric haemorrhage was associated with 37.5% of all SMO, the HIV seropositivity 
prevalence was 13.7% in the SMO group (less than in the general population).15 
In an analysis of data on 349 women who presented with hypovolemic shock from  
obstetric haemorrhage as part of a cluster-randomized controlled trial of the non-
pneumatic anti-shock garment in Zambia, it was found that HIV-infected women in 
hypovolemic shock had nearly double the odds of severe haemorrhage compared to 
HIV-uninfected women in hypovolemic shock.34 The observed increase in haemorrhage-
related maternal mortality in HIV-infected women was attributed to exacerbation of iron 
deficiency anaemia by pregnancy.34 
With regards to maternal deaths, an audit to assess the impact of expanded access to 
ART on maternal mortality at a Johannesburg tertiary hospital for the period 2003-2012, 
it was found that while deaths from tuberculosis and HIV-associated malignancy 
declined, mortality from obstetric haemorrhage in HIV-infected women did not change.35 
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The existing literature contains conflicting data about the interaction between HIV 
infection, ART and obstetric haemorrhage, with some suggesting a link and others 
suggesting no link. Given the limited data on the link between HIV infection and 
obstetric haemorrhage-related SMO, the aim of this study was to determine whether 
obstetric haemorrhage related severe maternal outcomes were increased in HIV-
infected women. The objectives of the study were: 
1. To assess the proportion of maternal deaths from obstetric haemorrhage, that 
occurred in HIV-uninfected and HIV-infected women at CHBAH from January 2015 to 
December 2015 
2.  To assess the proportion of cases of near-misses from obstetric haemorrhage, that 
occurred in HIV-uninfected and HIV-infected women at CHBAH from January 2015 to 
December 2015 
3. To compare factors that are associated with SMO related to obstetric haemorrhage in 
HIV-uninfected and HIV-infected women 
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CHAPTER THREE 
METHODS 
3.1 STUDY SETTING 
The study was conducted at CHBAH, a tertiary hospital and the largest hospital in 
Southern Africa, with the largest obstetrics unit in South Africa. The obstetrics unit at 
CHBAH serves as a referral centre for seven community health centres from the 
Greater Soweto area and for more distant areas, including centres outside the Gauteng 
province. There were 20,324 deliveries in the obstetrics unit at CHBAH in 2015. The 
HIV prevalence in pregnant women seen at the hospital is around 30%. The staff in the 
unit are led by a team of obstetricians and gynaecologists, and the unit is also a training 
centre for registrars, medical officers, interns and midwives.    
3.2 STUDY DESIGN 
This was a record review of cases of SAMM and maternal deaths, using antenatal and 
maternal records from the obstetric unit at CHBAH. Data from near-miss and maternal 
mortality audit reports conducted at CHBAH during the study period were used to 
supplement information from patients’ files. Any outstanding laboratory results not in the 
patient records were accessed on the National Health Laboratory Services (NHLS) 
Labtrak website https://trakcarelabwebview.nhls.ac.za. 
3.3 STUDY POPULATION 
The study population included cases of obstetric haemorrhage-related maternal deaths 
and SAMM at CHBAH’s obstetric unit, from 1 January 2015 to 31 December 2015. The 
management of all mothers with obstetric haemorrhage from the labour ward, antenatal 
wards, post-natal wards or theatre at CHBAH involves admission to the Obstetrics High 
Care area for monitoring and transfusion of blood products. Mothers are transferred to 
the adult intensive care unit (ICU) at CHBAH if they require inotropic support or artificial 
ventilation. In instances where ICU beds are not immediately available, mothers are 
managed in the Obstetrics High Care area while waiting to be transferred. When they 
are discharged from the adult ICU, they transit through the Obstetrics High Care area to 
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the post-natal wards. Cases were identified from the Obstetrics High Care area 
admissions register.  Patient records were obtained from the records department at in 
the obstetrics unit at CHBAH. Records of maternal deaths were retrieved from files that 
are kept in a dedicated area in the office of the Head of Department in the obstetrics 
unit. 
3.4 SUBJECTS 
3.4.1 Inclusion criteria 
• Pregnant women who died from obstetric haemorrhage, with a gestation age of 
at least 26 weeks. 
• Pregnant women who were managed for obstetric haemorrhage and met the 
WHO near-miss criteria. 
3.4.2 Exclusion criteria 
• Maternal deaths that were incidental or not related to the obstetric haemorrhage. 
• Near-miss cases that were not obstetric haemorrhage-related. 
• Women who were less than 26 weeks of gestation. 
3.5 DATA COLLECTION AND DATA ANALYSIS 
The broad criteria used to identify SAMM subjects from the Obstetrics High Care area 
register for potential inclusion in the study included: 
I. Any patients with APH or PPH who had been admitted from the obstetrics 
theatres or labour ward at CHBAH. Also, patients who were admitted from 
referring clinics that are part of the maternity complex and needed monitoring for 
obstetric haemorrhage 
II. Patients who had been admitted intrapartum or postpartum with a low 
haemoglobin concentration 
III. Patients who had been admitted for blood transfusion 
IV. Patients who had been admitted for ventilation 
V. Patients who were awaiting ICU admission and patients who had been admitted 
from ICU post-delivery 
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VI. Patients whose reasons for admission to the Obstetrics High Care area were not 
clear were also selected for possible inclusion. 
Gynaecological patients who had been admitted to the Obstetrics High Care area and 
monitored for bleeding were excluded. Women who developed SAMM were identified 
using the WHO organ dysfunction criteria for near-misses.  
All data were collected and analysed from February 2016 to October 2016. Antenatal, 
intrapartum and postpartum information on patients identified with obstetric 
haemorrhage-related SMO were extracted from the patients’ records using a structured 
questionnaire. (Appendix 1). Data were then captured on Research Electronic Data 
Capture (REDCap®)38 and exported onto and managed on Microsoft Excel 2010. 
Analysis was done with Stata®13.0 software. Continuous data were summarized using 
means and standard deviations (SDs), and medians with interquartile ranges (IQRs) as 
appropriate. Proportions and percentages were used for analysis of categorical data. 
Chi-squared test was used for inferential analysis of categorical data, and Student’s t-
test was used for comparison of means in normally distributed data, and statistical 
significance was accepted at p<0.05. 
3.6 ETHICS  
Ethical approval for this study was obtained from the University of the Witwatersrand’s 
Human Research Ethics Committee, Clearance Number: M151133 (Appendix 2). No 
names or any form of identification were used or entered onto the datasheet. Study 
numbers were assigned to patients’ names and hospital numbers and were collected on 
a separate document for follow-up and to allow for cross-checking of data. 
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CHAPTER FOUR  
RESULTS 
From 1 January to 31 December 2015, there were a total of 20 324 deliveries at 
CHBAH, and of these, 19 804 were live births. Using the broad criteria described in the 
data collection section, 222 cases were identified for potential inclusion in the study 
during the period and records were available for 166/222 (74.7%) of the cases. Of the 
166 records available, 73 cases of obstetric haemorrhage-related SMO were identified 
and 68/73 (93.2%) had a known HIV status and were included in the final analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 A summary of severe maternal outcomes with HIV status. 
 
A total of 18/68 (26.5%) women were HIV-infected and all of them were on the 
efavirenz-based fixed dose combination (FDC). Of the 18 HIV-infected women, 10/18 
(55.5%) were diagnosed prior to the index pregnancy and of these, 90% (9/10) were 
started on ART pre-pregnancy. The median CD4 count was 409 cells/mm3 (interquartile 
range (IQR) 222, 636), and viral load results were available for only three women. The 
viral load results were less than 20 copies/ml for two patients and 48 600 copies/ml for 
the other patient.  
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Of the 68 cases of SMO, 65 were SAMM and three were maternal deaths. Among the 
SAMM cases, 16/65 (24.6%) were HIV-infected, and of the three maternal deaths, two 
were in HIV-infected women.  
 
4.1 DEMOGRAPHICS AND ANTENATAL DETAILS 
The demographics of the 68 cases are presented in table 3.1 below. The mean age of 
HIV-infected women was 32.8 (SD± 5.8) years while that of HIV-uninfected women was 
29 (SD± 6.6) years, p=0.02. The median gravidity in HIV-infected women was 3 (IQR 2, 
4), and in HIV-uninfected women 2 (IQR 1, 3), p=0.04. Most women were booked, 
94.4% (17/18) of HIV-infected women and 96% (48/50) of HIV-uninfected women, with 
a mean gestational age at booking of 15.0±2.1 weeks and 17.6±6.4 weeks, 
respectively, p=0.60.  
A total of 24 women were diagnosed with anaemia antenatally, 8 (50.0%) HIV-infected 
and 18 (36.0%) HIV-uninfected, p=0.34. All women who were diagnosed with anaemia 
had iron deficiency anaemia and were treated with oral iron, with none receiving 
intravenous iron or blood transfusion. The haemoglobin at delivery was determined from 
the last known haemoglobin prior to, or at delivery. The definition of anaemia used was 
a haemoglobin <11g/dl. Overall, 15 women had at least one previous caesarean 
section, 6/18 (33.3%) of HIV-infected women and 9/50 (18%) of HIV-uninfected women, 
p=0.18.  
4.2 DELIVERY DETAILS 
The median gestational age at delivery in the HIV-infected women was 39 weeks, (IQR 
34, 40) and 38 weeks (IQR 35, 40) for the HIV-uninfected women, p<0.001. The onset 
of labour in majority of the women was spontaneous, 66.7% (12/18) in HIV-infected 
women and 74.0% (37/50) in HIV-uninfected women, p=0.60. Labour was induced with 
oral misoprostol in one woman; she was HIV-uninfected. Eleven percent (2/18) of HIV-
infected women, versus 14% (7/50) of HIV-uninfected received oxytocin for induction of 
labour, p=0.71. The median duration of labour was identical in both groups of women; 
720 minutes (IQR 545,1165) in HIV-infected women and 720 minutes (IQR 350,1365) in 
HIV-uninfected women, p=0.83. 
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Table 4.1: Demographics and antenatal details 
 HIV-infected 
 
n=18 
HIV-uninfected 
 
n=50 
p-value 
 Age in years, mean (SD) 32.5 (5.8) 29 (6.6) 0.02 
Age category, n (%)                                                  
<18 
 
0 (0.0) 
 
3 (6.0) 
 
0.28 
18-35 13 (72.2) 39 (78.0) 0.62 
≥35 5 (27.8) 8 (78.0) 0.27 
 Parity, median (IQR) 2 (1, 2) 1 (0, 2) 0.16 
  3 (2, 4) 1 (2, 3) 0.04 
Booked, n (%) 17 (94.4) 48 (96.0) 0.78 
Gestational age at booking, mean (SD) 15 (2.1) 17 (6.4) 0.60 
<20 weeks, n (%) 8 (53.3) 28 (62.2) 0.54 
≥20weeks, n (%) 7 (46.7) 17 (37.8) 0.55 
Previous caesarean section, n (%) 6 (33.3) 9 (18.0) 0.18 
Diagnosis of anaemia, n (%) 8 (50) 16 (36) 0.47 
Gestational age of anaemia diagnosis,  
mean (SD) 
23.5 (10.1) 20 (8.7) 0.63 
Haemoglobin at delivery, mean (SD) 9.6 (1.8) 11.7 (2.1) 0.97 
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Table 4.2: Labour and delivery details 
 HIV-infected 
n=18 
HIV-uninfected 
n=50 
p-value 
Gestation age at delivery, median (IQR) 39 (34, 40) 38 (35, 40) <0.001 
Onset of labour 
Spontaneous (%) 
 
12 (66.7) 
 
37 (74.0) 
 
0.60 
Induced (%)  0 1(2.0)  
Antepartum haemorrhage 6 (33.3) 7 (46) 0.35 
Mode of delivery, n (%)                    
NVD 
 
6 (33.3) 
 
14 (28.0) 
 
0.55 
Assisted 0 (0.0) 1 (2.0) 0.54 
EMCS 12 (66.7) 33(66.0) 0.90 
ELCS 0 (0.0) 2(4.0) 0.39 
Duration of labour in minutes, median (IQR) 720 (545,1165) 720 (350,1365) 0.83 
Indications for caesarean section, n (%)    
Antepartum haemorrhage of unknown origin 2 (11.1) 7 (14.0) 0.80 
Abruptio placenta 2 (11.1) 10 (20.0) 0.41 
Placenta praevia 0 (0.0) 3 (6.0) 0.08 
Prolonged labour 3 (16.7) 3 (6.0) 0.14 
Cephalopelvic disproportion 1 (5.6) 3 (6.0) 0.97 
Caesarean section duration, minutes, median (IQR) 87.5 (55,185) 100.0 (50,189) <0.001 
NVD= normal vaginal delivery; EMCS=emergency caesarean section; ELCS = elective 
caesarean section 
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The labour and delivery details are summarized in the table 4.2. The duration of labour 
was calculated from the documented onset of labour (rupture of membranes, detectable 
contractions, or cervical dilatation), whether spontaneous or induced, to the delivery of 
the fetus, regardless of mode of delivery.  
4.3 ANTEPARTUM HAEMORRHAGE 
Twenty nine of the 68 women (42.7%) in the study had SMO from APH. This number 
was made up of 33.3% (6/18) of HIV-infected women and 38.3% (23/60) of HIV-
uninfected women. The causes of APH are summarized in table 4.3. Thirteen of the 
women with abruptio placenta were initially managed as an APH of unknown origin with 
no known risk factors for abruptio placenta but were later confirmed to have had 
abruptio placenta after delivery. 
Table 4.3 Causes of Antepartum haemorrhage, n=29 
 HIV-infected 
n=6 
n (%) 
HIV-uninfected 
n=23 
n (%) 
Placenta praevia 0 (0.0) 3 (13.0) 
Abruptio placenta 4 (66.6) 19 (82.6) 
Uterine rupture 2 (33.3) 1 (4.4) 
 
4.4 POSTPARTUM HAEMORRHAGE  
Postpartum haemorrhage was diagnosed in most women (65/68; 95.6%) who had an 
obstetric haemorrhage-related SMO – 88.9% (16/18) in HIV-infected women and 98.9% 
(49/50) in HIV-uninfected women, (p=0.07). The causes of PPH in the women in this 
study are presented in figure 4.2. Most of the women had more than one cause of PPH. 
Other causes of PPH in the population included disseminated intravascular 
coagulopathy (HIV-infected) and placenta percreta (HIV-uninfected). The majority 
(64/67; 95.5%) of cases of PPH were diagnosed in the first 24 hours after delivery, i.e. 
primary PPH. Half (8/16) of HIV-infected women with PPH were diagnosed in the first 
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hour after delivery, compared to 73.5% (36/49) of HIV-uninfected women (p= 0.08). One 
HIV-infected woman had secondary PPH (diagnosed 7 days post-delivery). 
BDACS=Bleeding during or after caesarean section 
Figure 4.2: Causes of postpartum haemorrhage 
4.5 INTERVENTIONS USED IN THE MANAGEMENT OF POSTPARTUM 
HAEMORRHAGE  
Medical and surgical interventions were employed in the management of obstetric 
haemorrhage in the study population. Figure 4.3 gives a breakdown of the agents used 
in the medical management of obstetric haemorrhage; most women received more than 
one agent. 
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Figure 4.3: The frequency of medical agents used in the management of postpartum 
haemorrhage 
 
The surgical interventions used in the management of postpartum haemorrhage are 
presented below.
Figure 4.4: The frequency of surgical interventions used in the management of 
postpartum haemorrhage 
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4.6 BLOOD TRANSFUSIONS IN WOMEN WITH OBSTETRIC HAEMORRHAGE 
All 68 women in the study received blood products (red blood cells, fresh frozen plasma, 
platelets, and cryoprecipitate) ranging from at least one unit of blood to a total of 27 
units. A summary of the blood products received are presented below. 
 
 Figure 4.5: Amount of blood products transfused 
4.7 BLOOD RESULTS 
Table 4.4 presents the worst biochemistry and haematology results for both HIV-
infected and HIV-uninfected women during their hospital stay. There was a significant 
difference in the pH, lactate, base deficit and creatinine levels between the HIV-infected 
and HIV-uninfected women.  
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Table 4.4: Worst blood results during hospital admission 
 HIV-infected 
n=18 
HIV-uninfected 
n=50 
p-value 
Haemoglobin, mean (SD) g/dL 6.0 (1.89) 5.9 (1.36) 0.19 
Platelets, mean (SD)  
×109/L 
68 (23.2) 65 (23.5) 0.75 
pH, median (IQR)  7.2 (7.1, 7.26) 7.25 (7.2, 7.3) 0.004 
Bicarbonate, median (IQR) 
mmol/L 
15.5 (14.0, 16.1) 14 (11.4, 17.5) 0.97 
Lactate, median (IQR) mmol/L 5.5 (4.3, 8.8) 4.3 (3.2, 9.8) <0.001 
Creatinine, median (IQR) 
umol/L 
147 (137, 160) 137 (113, 208)           <0.001 
Base deficit, median (IQR) 
mEq/L 
12.6 (10.2, 15.8) 9.8 (7.2, 114) 0.01 
 
4.8 SEVERE MATERNAL OUTCOMES 
All 68 women in the study (maternal deaths and SAMM) were diagnosed with at least 
one organ system dysfunction. Many of them fell into more than one category. Relook 
laparotomy and ICU admission, both in the management criteria were included as 
markers of near-miss in the study. The occurrence of markers of near-miss is 
summarized in Table 3.5. Twenty-two women, (27.8%) HIV-infected and (34.0%), HIV-
uninfected in the study needed ventilator support, and were managed in either theatre 
or Obstetric High Care area while awaiting transfer to the main adult ICU. Duration of 
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ventilation ranged from one hour to 48 hours. The average duration of ventilation in HIV-
infected women was 12.3 (SD±0.6) hours and 14.6 (SD±0.5) hours in HIV-uninfected 
women, p=0.78. Massive blood transfusion was defined as receiving 5 or more units or 
blood products. 
Table 4.5: Markers for near-miss to obstetric haemorrhage 
 
  
HIV-infected 
n=18 
n (%) 
HIV-uninfected 
n=50 
n (%) p-value 
Massive transfusion 13 (72.2) 43 (86.0) 0.18 
Relook laparotomy 7 (38.9) 16 (32.0) 0.89 
Artificial ventilation   5(27.8) 17 (34.0) 0.62 
Hysterectomy   4 (22.2) 12 (24.0) 0.87 
ICU admission   1 (5.6) 9 (18.0) 0.20 
Hypoxemia   1 (5.6) 6 (12.0) 0.44 
Shock 1 (5.6) 6 (12.0) 0.44 
Oliguria 2 (11.1) 4 (8.0) 0.68 
Vaso-active drug use   1 (5.6) 3 (6.0) 0.94 
Cardiac arrest/CPR   0 (0.0) 2 (4.0) 0.39 
Need for dialysis   0 (0.0) 1 (2.0) 0.50 
Seizures  1 (5.6) 0 (0.0) 0.09 
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4.9 DETAILS OF THE MATERNAL DEATHS 
There were three maternal deaths related to obstetric haemorrhage in the study period. 
Two of them were HIV-infected and one was HIV-uninfected. 
4.9.1 Case 1 
The first maternal death case was a 28-year old gravida 2 para 0 old HIV-infected 
woman who was initiated on ART in the index pregnancy. Her CD4 count and viral load 
were unknown. She had mild anaemia (booking haemoglobin of 10.0 g/dL) and did not 
receive treatment for anaemia. She delivered vaginally at 39 weeks gestation, at a 
primary healthcare facility, and had primary PPH, diagnosed within one hour of delivery. 
The causes of the PPH were uterine atony and vaginal lacerations, and she had no 
identifiable intrapartum risk factors for PPH. There was a three-hour transportation 
delay in referring the patient from the primary healthcare facility to CHBAH, after the 
PPH was diagnosed.   
On arrival at CHBAH, the patient received oxytocin, syntometrine, tranexamic acid, and 
prostaglandin F2α as part of her medical management. When the medical management 
failed, surgical management was instituted, initially with a balloon tamponade, followed 
by a subtotal hysterectomy 60 hours later when she continued to bleed. She received a 
massive transfusion consisting of 15 units of red packed cells, 8 units of fresh plasma 
and 4 mega units of platelets in total. She spent 27 days in hospital and died of severe 
respiratory sepsis with multiple organ failure.  
4.9.2 Case 2 
The second maternal death case was a 35-year old gravida 3 para 1 HIV-infected 
woman who was on ART, initiated pre-pregnancy. Her antenatal CD4 count was 616 
cells/mm3. She booked at 9 weeks gestation, with a haemoglobin of 13.2 g/dL, and had 
a history of one previous lower uterine segment caesarean section. She was brought to 
hospital by ambulance and presented with a history of acute collapse at 29 weeks 
gestation. On arrival at CHBAH, cardiopulmonary resuscitation (CPR) was initiated. She 
had a perimortem caesarean section as part of ongoing CPR and was diagnosed with a 
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uterine rupture intraoperatively. She received 4 units of red packed cells, 4 units of fresh 
frozen plasma and 1 mega unit of platelets. She died within 7 hours of arrival in hospital. 
4.9.3 Case 3 
The third maternal death case was of a 32-year-old gravida 3 para 1 HIV-uninfected 
woman, who booked at 11 weeks with a normal haemoglobin. She had one previous 
caesarean section and was diagnosed with a placenta praevia major on ultrasound at 
31 weeks gestation. She was hospitalised until a planned elective caesarean section at 
36 weeks. Notably, her surgery was done by a registrar and placenta percreta was 
diagnosed intraoperatively, upon which a consultant was called to assist. She had a 
caesarean hysterectomy and a re-look laparotomy within an hour after the initial 
operation for on-going PPH. She developed a DIC and the abdomen was packed to aid 
haemostasis.  The patient had a relook laparotomy 48 hours later for removal of the 
abdominal packs. She received a massive transfusion with 7 units of red packed cells, 4 
units of fresh frozen plasma and 8 units of cryoprecipitate in total. She had a hypoxic 
event after the second re-look laparotomy followed by multiple seizures. She later had a 
cardiac arrest and died 12 days post-delivery after an unsuccessful CPR. She was in 
hospital for 65 days, including her antenatal stay. 
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CHAPTER FIVE 
DISCUSSION 
In this retrospective record review of cases of obstetric haemorrhage at CHBAH, from 
01 January to 31 December 2015, there was no difference in the incidence of obstetric 
haemorrhage-related near-misses and maternal deaths between HIV-infected and 
uninfected women. The HIV-infected women in the study were a relatively healthy 
group, with a median CD4 count of 409 cells/mm3 and all of them were on ART. 
Diagnosis and causes of obstetric haemorrhage did not differ between the HIV-infected 
and uninfected women.  
Previous caesarean section was the commonest identifiable risk factor for obstetric 
haemorrhage that was identified, and nearly a quarter of the women in the study had a 
previous caesarean section. The finding of such a significant proportion of previous 
caesarean section related SMO agrees with Maswime et al in their description of risk 
factors for maternal death due to BDACS in Johannesburg (July to December 2014).23 
They identified previous caesarean section as one of the most important common risk 
factors for near-miss.23 With the increasing rate of caesarean section deliveries in South 
Africa, this finding reflects the increasing importance of previous caesarean section as a 
risk factor for obstetric haemorrhage-related severe maternal outcomes.  
5.1 ANTENATAL AND INTRAPARTUM FACTORS ASSOCIATED WITH OBSTETRIC 
HAEMORRHAGE 
More than a third of women in the study had anaemia at the first antenatal visit. 
Adhering to the recommendations from the sixth Saving Mothers report to prevent 
anaemia as a measure to prevent obstetric haemorrhage related deaths,4 the mean 
haemoglobin concentrations of the women in the study had improved with oral 
haematinics by the time of delivery. In all the HIV-uninfected women, the haemoglobin 
levels were normal at the time of delivery, while HIV-infected women were still mildly 
anaemic. Anaemia was however not associated with severe obstetric haemorrhage-
related maternal outcomes in this study. Correction of antenatal anaemia appears to 
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have decreased the risk for obstetric haemorrhage in both HIV-infected and uninfected 
women. 
The duration of the caesarean sections was significantly longer in HIV-uninfected 
women. This is difficult to explain, especially as it is rather expected that HIV-infected 
women who were significantly older and had a higher parity, would be more likely to 
have had a previous caesarean section, and therefore a longer caesarean section 
duration than uninfected women. The long duration of caesarean sections in both HIV-
infected women (median 100 minutes) and uninfected women (median 87.5 minutes) in 
the study is worth noting. While comparing caesarean section surgical techniques in 
over 15 000 women in the CORONIS trial, secondary outcomes were measured. The 
incidence of ICU admission and postpartum haemorrhage were not increased in their 
study and a median duration of the operation of 40 minutes was deemed acceptable. 20 
The finding in my study represents a more than twofold increase in the acceptable 
average caesarean section duration as demonstrated in the CORONIS study.20 
Typically, junior members of the team are assigned to perform caesarean sections. 
Though their competencies are verified before they work unsupervised, the prolonged 
duration of surgery in this study may reflect both the relative inexperience of the 
surgeons and the inherent difficulty encountered during caesarean sections for women 
who end up with severe outcomes. The extended operating time also reflects the time 
needed to correct the underlying pathology associated with a severe outcome. The 
contribution of BDACS to maternal deaths at district and secondary level facilities is well 
recognized,19 but this study brings to the fore the importance of BDACS as a significant 
factor associated with adverse pregnancy outcomes at all levels of care when near-
misses are also studied. 
Prolonged labour was associated with 8.8% of SMO in this study and there was no 
significant difference in the duration of labour between HIV-infected women and 
uninfected women. This association of prolonged labour with maternal near-miss is 
consistent with findings by Pacagnella et al in their descriptions of delays associated 
with severe maternal outcomes.10 In contrast with the sixth Saving Mothers report 
however, prolonged labour was not associated any deaths in this study.4  
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5.2 CAUSES OF OBSTETRIC HAEMORRHAGE 
There was no significant difference in the causes of obstetric haemorrhage between 
HIV-infected and HIV-uninfected women. The incidence of uterine atony retained 
placenta, uterine rupture, abruptio placenta and genital tract tears, as causes of 
obstetric haemorrhage, did not differ between HIV-infected and HIV-uninfected women. 
PPH was the leading cause of obstetric haemorrhage-related SMO in this study. The 
incidence of PPH was not increased in HIV-infected women. This agrees with the 
findings from the systematic review and meta-analysis by Calvert et al who also found 
that there was no evidence that HIV increases the odds of postpartum haemorrhage.36 
Three women had placenta praevia and all of them were HIV-2uninfected. It appears to 
be coincidental with no explanation to suggest that seropositivity may be protective 
against placenta praevia. There was no difference in the incidence of abruptio placenta 
and uterine rupture between HIV-infected and uninfected women, and this is consistent 
with findings from the systematic review by Calvert et al. 36 The incidences of other 
causes of PPH (uterine atony, retained placenta and genital tract tears) followed a 
similar trend of no demonstrable difference between HIV-infected and HIV-uninfected 
women. This was however contrary to the findings by Shabalala et al who found that 
HIV increased the risk of PPH in a study done in Durban, South Africa (2009-2011). 37 It 
must be noted that my study and that of Shabalala et al were done during different ART 
guideline eras. 24–29 The improvement in anaemia and general health of HIV-infected 
women in this study, from improved ART regimens, is likely to explain why they were 
not at an increased risk of obstetric haemorrhage. 
5.3 INTERVENTIONS USED IN THE MANAGEMENT OF POSTPARTUM 
HAEMORRHAGE 
In the management of PPH, pharmacological agents and surgical techniques were 
employed. There was no significant difference in the requirements for oxytocin, 
ergometrine, syntometrine, prostaglandin F2α, tranexamic acid and misoprostol 
between HIV-infected and HIV-uninfected women. Neither did evacuation of uterus, 
uterine compression sutures, balloon tamponade, repair of genital tract injury, 
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hysterectomy nor systematic devascularization occur more frequently in one group than 
the other.  
All the women in this study were transfused with blood products. The HIV-infected 
women received similar amounts of total blood products as the HIV-uninfected women. 
The amount of red blood cells, platelets and cryoprecipitates received did not differ 
significantly between HIV-infected women and uninfected women. This finding differs 
from what Bloch et al found in their cross-sectional study of peripartum patients in South 
Africa.16 In their study to determine the incidence and predictors of transfusion in 
relation to HIV infection, they found significantly higher risk of peripartum transfusion in 
HIV-infected patients than uninfected women.16 They attributed their findings to a high 
prevalence of unaddressed antenatal anaemia among HIV-infected women. In my study 
however, all iron deficiency anaemia had been corrected prior to delivery and that may 
explain why the total blood products received did not differ between HIV-infected and 
uninfected women. The HIV-infected women received slightly less units of fresh frozen 
plasma (4 vs 2.5 units, p=0.28) than infected women. HIV-infected women are rather 
expected to be more likely to have clotting disorders than uninfected women and would 
therefore require more units of fresh frozen plasma to help manage bleeding. This was 
another unexpected finding in my study as seropositivity is not expected to confer 
protection from transfusion with fresh frozen plasma. 
5.4 NEAR-MISSES AND MATERNAL DEATHS 
Massive transfusion, artificial ventilation, hysterectomy, hypoxemia, shock, and oliguria, 
in order of decreasing frequency, occurred at similar rates among HIV-infected and 
uninfected women. Other markers for near-misses which occurred to lesser degrees like 
continuous use of vaso-active drugs, cardiac arrest (with cardiopulmonary 
resuscitation), requirement for dialysis and seizures followed a similar pattern. Relook 
laparotomy and ICU admission which are management-based criteria for near-miss, 
included as markers of near-miss in this study because of their frequency, also showed 
no differences in incidence when HIV-infected women were compared to HIV-uninfected 
women. The finding of no difference in near-miss between HIV-infected and HIV-
uninfected is similar to that reported by Soma-Pillay et al in 2014, who found no 
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correlation between HIV status and obstetric haemorrhage-related maternal near-
misses.15.  
There were three obstetric haemorrhage-related maternal deaths in the study period; 
two in HIV-infected women and one in an uninfected woman. They all required massive 
transfusion of blood products. The number of deaths in this study was too small for any 
attributions to be made to the HIV status of the women who died. The deaths highlight 
some of the important events that lead to maternal deaths nationally at all levels of care. 
Previous caesarean section was the underlying risk factor leading to the deaths of two 
of the women; one HIV-infected, the other uninfected. One woman had a uterine rupture 
remote from term, with severe antepartum haemorrhage and required a peri-mortem 
caesarean section as part of a resuscitation which was unsuccessful. The use of illegal 
uterotonics is known to be common among women in the Greater Soweto area, for 
inducing labour and termination of pregnancy. It was not clear from the limited 
information available that any such substance was used. A catastrophic uterine rupture 
through the previous caesarean section scar is the only possible explanation. This 
death was probably unavoidable. Another had a planned caesarean section for placenta 
praevia, done by a junior surgeon without the requisite skill to manage complications 
associated with placenta praevia. This was an avoidable death. The other death was 
due to delays on two levels: a transportation delay (administrative delay) in referring the 
patient to the tertiary facility, and a delay in instituting definitive management (health 
worker related). These delays are mirrored in the Brazilian multi-centre study in 2014 by 
Pacagnella et al in which they noted that transportation delays, untimely and improper 
management were significantly associated with maternal deaths.10 
Buchmann et al in a retrospective cross-sectional study to determine causes and trends 
of maternal deaths in Johannesburg (1997 to 2012) suggested that it was likely that 
sustainable strengthening of HIV diagnosis and ART programmes would reduce deaths 
from direct obstetric causes.12 All the HIV-infected women in my study were on 
treatment and generally healthy. The result of the current ART guideline where all 
pregnant women became eligible to initiate ART may have achieved the desired results 
in reducing deaths from obstetric haemorrhage. 
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5.5 LIMITATIONS 
A limitation of this study is that it was a retrospective study and the sample was small. 
Also, poor recording of entries in the obstetric high care admissions register made 
patient identification difficult. This limitation was overcome by making the inclusion 
criteria wide so that no patients would be missed. Another limitation was the poor filing 
of patients’ records in the records department, due to lack of space. This made retrieval 
of patient records difficult, but eventually 75% of patient records were found. Another 
important limitation was that the HIV status of five women with severe maternal 
outcomes were unknown and were therefore excluded from the study. Furthermore, an 
association between HIV viral load and severe maternal outcomes could not be 
established because viral load levels were measured in only three women. 
5.6 STRENGTHS 
The strength of this study is that although the sample size was small, very detailed 
information could be collected for each patient. The detailed analysis of data allowed for 
good examination of factors associated with severe maternal outcomes. It is unlikely 
that women with severe maternal outcomes related to obstetric haemorrhage were 
missed as the obstetric high care area is a central point where all mothers with life-
threatening conditions transit through from theatre, labour or antenatal ward to the post-
natal wards or ICU. Wide inclusion criteria were also used to identify patients for 
potential inclusion into the study. 
5.7 CONCLUSION 
In this study, there was no significant difference in obstetric haemorrhage-related severe 
maternal outcomes in HIV-infected women compared to HIV-uninfected women. This 
may be because it was a relatively healthy population of HIV-infected women, with a 
high median CD4 count and all of them were on ART. The antenatal and intrapartum 
risk factors for maternal near-miss and maternal deaths were similar between the two 
groups. Previous caesarean section was the commonest underlying risk factor for 
obstetric haemorrhage. Larger studies are needed to describe these findings in better 
detail. 
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5.8 RECOMMENDATIONS 
A great deal of attention needs to be given to the training of junior staff on the clinical 
and surgical management of women with postpartum haemorrhage. Doctors in referral 
centres should be better trained to safely perform caesarean sections and to 
appropriately manage associated complications. The recommendation from the sixth 
Saving Mothers report to provide onsite emergency transport from district hospitals to 
higher centres should be upscaled. Lastly, there needs to be improvement in the routine 
viral load monitoring of HIV-infected women, especially during pregnancy and for long 
term management. 
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APPENDICES  
Appendix 1: Data Collection Tool 
STUDY ID [  ][  ][  ] 
Date of data collection: ________    
A. ANTENATAL INFORMATION 
Age: ____ years  Gravidity: ____  Parity: ____ 
Summary of previous pregnancies: 
Year  Outcome Mode of 
delivery 
Birth weight Gestation at 
delivery 
Complications 
 
 
     
 
 
     
      
      
 
Booked Unbooked  Date of booking ________________ 
Gestational age at booking: _____ weeks 
Place of booking; specify 
Clinic ________ Hospital Level 1  Hospital Level 2  Tertiary Hospital  
Private  
1. Booking bloods:  
Booking Haemoglobin: ____ g\dL 1st repeat ____g\dL 2nd repeat ____g\dL 
3rd repeat ____g\dL 
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Rhesus: Positive  Negative  Unknown           
RPR: Positive  Negative  Unknown 
2. Information on HIV disease 
HIV status: Positive Negative  Unknown     
If negative  1st repeat date___________ 2nd repeat date____________ 
Period of diagnosis of HIV: Prepregnancy Antenatal Intrapartum 
Post-partum 
If positive CD4 count: ____cells/mm3 
Date of latest CD4 count testing ____________ Gestational age at which CD4 
was done______ weeks 
On Antiretrovirals: Yes  No  Unknown 
When where ARVs started? Prepregnancy Antenatal Intrapartum 
Post-partum 
Duration of treatment at time of incident (SAMM/Mortality) ________years 
Which treatment? 
FDC TDF  FTC  3TC  AZT  D4T  EFV 
NVP  Alluvia Other; specify__________  Information not available 
Any treatment switches/failure? Yes  No 
Viral load at booking ___ copies/ml Not available 
Latest Viral load ___ copies/ml  
Date ____________  Gestational age at which viral load was done______ weeks 
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3. Comorbidities in the index pregnancy 
Diabetes Mellitus (IDDM/NIDDM) Chronic hypertension Asthma      
Epilepsy Tuberculosis    Hypothyroidism   Hyperthyroidism 
Cardiac disease  Other(s); specify_______________________     
Chronic medication(s), 
Haematinics:   Ferrous sulphate   Folic acid 
Vitamins:  Vitamin C 
Antihypertensives: Lisinopril  Enalapril Hydrochlorothiazide  
Methyldopa  Nifedipine  Other(s) please specify ____________ 
Anticoagulants:  Warfarin Aspirin Fractionated heparin  
Hypoglycaemics: Metformin Gliclazide Pioglitazone Insulin  
Antiepileptics _______________________   
Anti-TB treatment  _______________________    
4. Information on diagnosis and management of anaemia 
Was the patient diagnosed with anaemia during the pregnancy? Yes No  
Severity of anaemia:  
Mild 9.0-10.9g/dL Moderate 7.0-8.9g/dL  Severe Less than 7g/dL 
Gestational age at diagnosis of anaemia _____weeks  Date__________ 
Was she treated for anaemia during the pregnancy?  Yes  No 
If treated for anaemia, where was she treated? 
Local clinic  CHBH Antenatal clinic CHBH ANC Anaemia Clinic  
Other; specify___________ 
Gestational age at treatment of anaemia ______weeks  Date__________ 
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Cause of anaemia identified? Yes; specify ____________ No 
Treatment available at facility? Yes   No 
Gestational age at referral to CHBAH _____weeks   Date__________ 
When seen at CHBH? Gestational age_____ weeks  Date___________ 
Did the patient receive any of the following during the pregnancy? 
Oral haematinics  Parenteral (IV) iron Blood transfusion 
Reason for receiving parenteral iron 
Not absorbed Not tolerated   Close to delivery 
Reason for receiving blood transfusion 
Severe anaemia  Symptomatic anaemia  Obstetric indication 
Last haemoglobin level at delivery ____g/dL Haemoglobin corrected? Yes No 
Was the patient diagnosed with thrombocytopenia during the pregnancy? Yes No  
Cause; specify ______________ 
Was the patient admitted at any time during the index pregnancy?   Yes  No  
If admitted, reason for admission: 
Threatened miscarriage   Excessive vomiting in pregnancy  
Prelabour rupture of membranes Preterm labour  Chorioamnioinitis 
Lower respiratory tract infection  Other non-pregnancy related infections 
Hypertension in pregnancy  Antepartum haemorrhage    
Postdates   Other(s) ______________ 
Comments_____________________________________________________________
_______________________________________________________________ 
 
42 
 
B. INTRAPARTUM DETAILS 
Onset of labour  Date___________ Time_________________ 
Spontaneous  Induced. If induced what was the indication? ______________ 
Duration of induction _____hours  
Induction agent 
Oral Misoprostol   Vaginal Misoprostol  Prostaglandin gel  
Oxytocin Catheter induction 
Was there prolonged rupture of membranes   Yes   No 
If yes, what was the duration? ____hours 
Were antibiotics given? Yes   No 
If yes, which antibiotic(s) 
Ampicillin  Metronidazole Erythromycin  
Co Amoxicillin-Clavulanic acid Other(s)  
Was labour augmented? Yes   No 
If yes, duration of augmentation _______hours 
Intrapartum Diagnosis 
Singleton  Multiple gestation  Cephalic presentation  
Breech presentation  Transverse lie  Preeclampsia  
 Other; specify _______________ 
Was antepartum haemorrhage diagnosed? Yes   No 
If yes, was it… 
Placenta praevia Suspected abruptio placenta Confirmed abruptio placenta 
APH of unknown origin  Other; specify _______________ 
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Date of delivery___________ Time of delivery_______________  
Gestational age at delivery ____weeks. 
Intra partum diagnosis of chorioamnioinitis? Yes   No 
Place of delivery: 
Home En route to hospital  Clinic Hospital Level 1    
Hospital Level 2     Tertiary Hospital 
Mode of delivery:  
Normal vaginal delivery  Assisted vaginal delivery   
Emergency caesarean section Elective caesarean section 
Indication(s) for caesarean section: 
_______________________________________________________ 
Date and time of Caesarean section ____________________  
Duration of Caesarean section _______minutes 
Total duration of labour ____________minutes 
If referred from local clinic, was there a delay in referral to hospital Yes  No 
Reason for delay: 
Patient related Healthcare worker related Administrative related  
Other (specify) ____________ 
C: POSTPARTUM DETAILS 
Was postpartum haemorrhage diagnosed?  Yes   No 
If yes, was it  Primary  or Secondary 
How soon after delivery was PPH diagnosed?  
Immediately after delivery Within 1st hour of delivery  
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More than 1 hour after delivery  Other; _____ specify hours/days 
Cause of postpartum haemorrhage 
 Retained placenta  Cervical trauma   Vaginal trauma  Perineal tears  
 Uterine atony  Uterine rupture  Bleeding after Caesarean  
 Other(s) specify____________________  
Management of postpartum haemorrhage: 
Medical management: 
Oxytocin Syntometrine Ergometrine Prostaglandin F2α 
Tranexamic acid   Other (s) ________specify 
Surgical management:  
 Evacuation of uterus Uterine compression sutures Balloon tamponade  
Repair of genital tract injury  Systematic devascularization  Hysterectomy 
Uterine artery ligation 
Time between vaginal delivery and repair of genital tract injury _____hours 
Time between vaginal delivery and evacuation of uterus and, or removal of placenta 
_____hours 
Time between caesarean section and hysterectomy/ surgical management _____hours 
Time between initial operation and relook laparotomy _____hours 
Category of SMO  
 Severe Acute Maternal Morbidity  Maternal Mortality  
SAMM Criteria 
ICU Admission Hysterectomy  Relook Laparotomy    
Artificial ventilation/intubation not related to anaesthesia Acute cyanosis       
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Gasping Severe tachypnoea (respiratory rate >40 breaths/min)    
Severe hypoxemia (02 <90%)  Massive transfusion of blood products (≥5units) 
Shock  Cardiac arrest  Continuous vaso active drugs  
Cardiopulmonary resuscitation Oliguria Need for dialysis   
Cardiopulmonary resuscitation Prolonged unconsciousness  
Stroke  Fits   Paralysis 
D. BLOOD RESULTS AND TIMING 
  1 hour 6hours 12hours 24hours 48hours 120hours 168hours 
pH        
Base excess        
Haemoglobin        
Haematocrit        
Platelets        
Glucose        
Lactate        
Urea        
Creatinine        
Bicarbonate        
 
Bilirubin        
 
Duration of ICU stay _____days 
Duration of artificial ventilation/Intubation _____hour(s) 
Blood products given 
Red cell _____units  Fresh frozen plasma _____units  
Platelets _____mega units  Cryoprecipitate_______ units  
Duration of hospital stay _______day(s) 
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If maternal death, cause of death__________________________ 
Date__________ 
Time 
Place of death___________________ 
Time (minutes/hours) between delivery and death__________ 
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